亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

依维莫司 医学 内科学 安慰剂 双盲 肾细胞癌 肿瘤科 泌尿科 病理 替代医学
作者
Robert J. Motzer,Bernard Escudier,Stéphane Oudard,Thomas E. Hutson,Camillo Porta,Sergio Bracarda,Viktor Grünwald,John A. Thompson,Robert A. Figlin,Norbert Hollaender,Gladys Urbanowitz,William J. Berg,Andrea Kay,David Lebwohl,Alain Ravaud
出处
期刊:The Lancet [Elsevier BV]
卷期号:372 (9637): 449-456 被引量:2951
标识
DOI:10.1016/s0140-6736(08)61039-9
摘要

Background Everolimus (RAD001) is an orally administered inhibitor of the mammalian target of rapamycin (mTOR), a therapeutic target for metastatic renal cell carcinoma. We did a phase III, randomised, double-blind, placebo-controlled trial of everolimus in patients with metastatic renal cell carcinoma whose disease had progressed on vascular endothelial growth factor-targeted therapy. Methods Patients with metastatic renal cell carcinoma which had progressed on sunitinib, sorafenib, or both, were randomly assigned in a two to one ratio to receive everolimus 10 mg once daily (n=272) or placebo (n=138), in conjunction with best supportive care. Randomisation was done centrally via an interactive voice response system using a validated computer system, and was stratified by Memorial Sloan-Kettering Cancer Center prognostic score and previous anticancer therapy, with a permuted block size of six. The primary endpoint was progression-free survival, assessed via a blinded, independent central review. The study was designed to be terminated after 290 events of progression. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00410124. Findings All randomised patients were included in efficacy analyses. The results of the second interim analysis indicated a significant difference in efficacy between arms and the trial was thus halted early after 191 progression events had been observed (101 [37%] events in the everolimus group, 90 [65%] in the placebo group; hazard ratio 0·30, 95% CI 0·22–0·40, p<0·0001; median progression-free survival 4·0 [95% CI 3·7–5·5] vs 1·9 [1·8–1·9] months). Stomatitis (107 [40%] patients in the everolimus group vs 11 [8%] in the placebo group), rash (66 [25%] vs six [4%]), and fatigue (53 [20%] vs 22 [16%]) were the most commonly reported adverse events, but were mostly mild or moderate in severity. Pneumonitis (any grade) was detected in 22 (8%) patients in the everolimus group, of whom eight had pneumonitis of grade 3 severity. Interpretation Treatment with everolimus prolongs progression-free survival relative to placebo in patients with metastatic renal cell carcinoma that had progressed on other targeted therapies. Funding Novartis Oncology.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
17秒前
科研通AI2S应助科研通管家采纳,获得10
19秒前
Ma发布了新的文献求助10
23秒前
1234完成签到,获得积分10
35秒前
岁和景明完成签到 ,获得积分10
38秒前
科研通AI5应助Ma采纳,获得10
41秒前
西蓝花香菜完成签到 ,获得积分10
48秒前
1分钟前
1分钟前
2分钟前
科研通AI2S应助科研通管家采纳,获得10
2分钟前
科研通AI2S应助科研通管家采纳,获得10
2分钟前
Ma发布了新的文献求助10
2分钟前
2分钟前
科研通AI5应助Ma采纳,获得10
2分钟前
忧伤的绍辉完成签到 ,获得积分10
2分钟前
隐形曼青应助易四夕采纳,获得10
2分钟前
3分钟前
易四夕发布了新的文献求助10
3分钟前
3分钟前
4分钟前
Ma发布了新的文献求助10
4分钟前
4分钟前
随机子发布了新的文献求助10
4分钟前
4分钟前
Ava应助科研通管家采纳,获得10
4分钟前
科目三应助科研通管家采纳,获得10
4分钟前
科研通AI2S应助科研通管家采纳,获得10
4分钟前
Ma发布了新的文献求助10
4分钟前
Ma完成签到,获得积分10
5分钟前
5分钟前
易四夕发布了新的文献求助10
5分钟前
6分钟前
6分钟前
英姑应助王大壮采纳,获得10
6分钟前
SciGPT应助科研通管家采纳,获得10
6分钟前
6分钟前
6分钟前
6分钟前
Mine发布了新的文献求助10
6分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Immigrant Incorporation in East Asian Democracies 600
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3968504
求助须知:如何正确求助?哪些是违规求助? 3513278
关于积分的说明 11167214
捐赠科研通 3248660
什么是DOI,文献DOI怎么找? 1794386
邀请新用户注册赠送积分活动 875030
科研通“疑难数据库(出版商)”最低求助积分说明 804638